Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) – Equities researchers at Zacks Research issued their Q1 2025 earnings estimates for Apellis Pharmaceuticals in a research note issued on Wednesday, June 21st. Zacks Research analyst A. Chakraborty expects that the company will post earnings per share of $0.02 for the quarter. The consensus estimate for Apellis […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shot up 6.6% during mid-day trading on Wednesday . The company traded as high as $92.61 and last traded at $92.15. 1,237,443 shares traded hands during trading, a decline of 28% from the average session volume of 1,708,727 shares. The stock had previously closed at $86.42. Wall Street […]
Moore Capital Management LP trimmed its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 94.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,000 shares of the company’s stock after selling 169,958 shares during the quarter. Moore Capital Management […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price hoisted by Oppenheimer from $96.00 to $108.00 in a research note issued to investors on Friday morning, The Fly reports. APLS has been the topic of a number of other reports. Robert W. Baird raised their price target on shares of Apellis Pharmaceuticals from $90.00 […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the […]